tmmonline.nz  |   landlords.co.nz        About Good Returns  |  Advertise  |  Contact Us  |  Terms & Conditions  |  RSS Feeds

NZ's Financial Adviser News Centre

GR Logo
Last Article Uploaded: Sunday, September 20th, 11:42AM

Insurance

rss
Latest Headlines

Tower launches cover for non-Pharmac funded cancer drugs

Tower Health & Life has launched a new cover option for non-Pharmac funded cancer drugs which strikes a balance between giving customers the choice to include the cover while ensuring its base product is not vulnerable to sustainability issues.  

Tuesday, August 24th 2010, 12:17PM 1 Comment

It has overhauled its Premier Health trauma add-on option known as Serious Condition Lump Sum Option, introducing a Cancer Assistance Benefit.

This benefit will pay an additional amount of up to twice the sum insured if a non-Pharmac funded chemotherapy drug approved by Medsafe is recommended by the registered specialist for cancer treatment. This payment is over and above the trauma payout.

Tower Health & Life head of products and marketing Grant Hill says  the future cost of non-Pharmac funded cancer drugs is unknown with an ageing population placing greater demand on New Zealand's limited health dollar combined with pharmaceutical companies investing significant capital in trying to develop the next cancer wonder drug.

He says if non-Pharmac funded cancer drugs were covered under a health product's base module there would be a significant risk that it could drive much higher levels of claims' inflation.

"By extending the cover for non-Pharmac funded cancer drugs within the Serious Lump Sum add-on option, we believe we have struck the right balance between giving customers the choice to include this cover while ensuring our base product is not vulnerable to sustainability issues."

Tower has also increased the number of trauma conditions from 17 to 39 and they include Coronary Artery Angioplasty (three vessels or more), Cardiomyopathy, Advanced Dementia, Muscular Dystrophy and Parkinson's Disease.

A Children's Benefit has been introduced which pays out 50% of the sum insured on diagnosis of a defined trauma condition by an insured person's child aged between 3 and 18 regardless of whether the insured person's child is on their health policy and there is also a new Paralysis Assistance Benefit which pays an additional amount equal to the sum insured.

TOWER Health & Life chief executive Steve Boomert says these enhancements are very material and make Premier Health's Serious Condition Lump Sum Option a stand out in the marketplace.

"As health insurers come under increasing pressure to address affordability, we strongly believe that trauma cover will become more important as a logical and complimentary add-on option."

« Pre-tax change push to sell life policies helps AMPMixed reviews from advisers on FMA regulation »

Special Offers

Comments from our readers

On 30 August 2010 at 9:04 am beaudesert said:
Very good of Tower for finaslly waking up to the fact that the issue of Non Pharmac Drugs wont go away. Now they may stop criticising the other Insurer ING Life who have provided this benefit for many years. Also, readers need to be aware that the cover only extends to Life threatening cancer treatment, so all the many other non pharmac drugs that are not cancer realted, will NOT be covered by this policy.My advice, read the small print, I have, perhaps you should too.Having said all that,its a much better solution for Tower, clearly they were losing business in the market.
Commenting is closed

 

print

Printable version  

print

Email to a friend
Insurance Briefs

AIA adds grocery discounts to Vitality
AIA New Zealand has added a healthy food benefit to its Vitality programme, giving eligible insurance customers discounts of up to 25% on fresh fruit and vegetables at Woolworths.

Intelligent claims management platform arrives
Simfuni launches intelligent claims management product, future-proofing life insurers for the AI automation era.

Spurs and Auckand FC to meet in Auckland
AIA NZ is the Major Partner for Tottenham Hotspur’s return to New Zealand, with the team set to face Auckland FC at Eden Park later this year.

Fidelity Life keeps its rating for another year.
Fidelity Life has once again had its A- (Excellent) financial strength rating affirmed by AM Best.

News Bites
Latest Comments
  • FMA CEO on leave
    “@Murray: The reps seemed to be acting on their personal interests rather than the interests of advisers. Conflict of interest,...”
    4 Aug 2026 by w k
  • KiwiSaver funds shake off Middle East tension
    “In this recent presentation of mine https://www.knowrisk.co.nz I show that the average Balanced KiwiSaver fund has added...”
    4 Aug 2026 by P Urbani
  • FMA CEO on leave
    “@pragmatic The most elegant description of what you are talking about was retired Chief Justice of Australia speaking at...”
    3 Aug 2026 by Murray D Weatherston
  • Are we doing right by our clients when it comes to TPD?
    “Great article, Kat. The problem is that none of this feels real to people until it is. I'm as guilty as anyone. Death...”
    3 Aug 2026 by Own Occupation
  • FMA CEO on leave
    “There is real heat in the criticism aimed at the regulator, but it is pointed at the wrong target. The serious charge is...”
    3 Aug 2026 by Pragmatic
Subscribe Now

Cover Notes - Specific news aimed at risk advisers

Previous News
Most Commented On
About Us  |  Advertise  |  Contact Us  |  Terms & Conditions  |  Privacy Policy  |  RSS Feeds  |  Letters  |  Archive  |  Toolbox  |  Disclaimer
 
Site by Web Developer and eyelovedesign.com
x